IL93562A - A medicinal product containing D-cyclocarine and D-alanine - Google Patents

A medicinal product containing D-cyclocarine and D-alanine

Info

Publication number
IL93562A
IL93562A IL9356290A IL9356290A IL93562A IL 93562 A IL93562 A IL 93562A IL 9356290 A IL9356290 A IL 9356290A IL 9356290 A IL9356290 A IL 9356290A IL 93562 A IL93562 A IL 93562A
Authority
IL
Israel
Prior art keywords
cycloserine
glycine
alanine
memory
nmda
Prior art date
Application number
IL9356290A
Other languages
English (en)
Hebrew (he)
Other versions
IL93562A0 (en
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL93562A0 publication Critical patent/IL93562A0/xx
Publication of IL93562A publication Critical patent/IL93562A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
IL9356290A 1989-03-15 1990-02-27 A medicinal product containing D-cyclocarine and D-alanine IL93562A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
IL93562A0 IL93562A0 (en) 1990-11-29
IL93562A true IL93562A (en) 1996-01-31

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9356290A IL93562A (en) 1989-03-15 1990-02-27 A medicinal product containing D-cyclocarine and D-alanine

Country Status (17)

Country Link
US (1) US5061721A (de)
EP (1) EP0387867B1 (de)
JP (1) JP2963720B2 (de)
KR (1) KR900013961A (de)
AT (1) ATE88890T1 (de)
AU (1) AU624917B2 (de)
CA (1) CA2010635C (de)
DE (1) DE69001503T2 (de)
DK (1) DK0387867T3 (de)
ES (1) ES2055197T3 (de)
FI (1) FI901289A0 (de)
GR (1) GR3008225T3 (de)
IE (1) IE64130B1 (de)
IL (1) IL93562A (de)
NO (1) NO901198L (de)
NZ (1) NZ232809A (de)
PT (1) PT93424B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
EP0691844A1 (de) * 1993-03-29 1996-01-17 Queen's University At Kingston Verfahren zur behandlung von amyloidosis
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
EP0809624B1 (de) * 1995-02-15 2001-08-29 Bearsden Bio, Inc. Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
WO1998003189A1 (en) 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1383465B1 (de) * 2001-03-29 2011-08-10 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
EP1389181A4 (de) * 2001-04-02 2005-10-19 Panorama Res Inc Nitroxid- und nitron-antioxidationsmittel als therapeutika
EP1383497B1 (de) * 2001-05-02 2008-10-15 Blanchette Rockefeller Neurosciences Institute Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
EP1487542A1 (de) * 2002-03-15 2004-12-22 H. Lundbeck A/S Verwendung von asc-1-hemmern zur behandlung von neurologischen und psychiatrischen erkrankungen
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7544478B2 (en) * 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
JP2007517049A (ja) 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
MX2012009388A (es) 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
WO2012104852A1 (en) * 2011-01-31 2012-08-09 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
US5061721A (en) 1991-10-29
PT93424B (pt) 1996-08-30
DE69001503T2 (de) 1993-09-09
AU624917B2 (en) 1992-06-25
JPH03148221A (ja) 1991-06-25
IE900921L (en) 1990-09-15
NO901198D0 (no) 1990-03-14
JP2963720B2 (ja) 1999-10-18
ES2055197T3 (es) 1994-08-16
GR3008225T3 (de) 1993-09-30
DE69001503D1 (de) 1993-06-09
IL93562A0 (en) 1990-11-29
IE64130B1 (en) 1995-07-12
ATE88890T1 (de) 1993-05-15
CA2010635A1 (en) 1990-09-15
KR900013961A (ko) 1990-10-22
EP0387867B1 (de) 1993-05-05
AU5073490A (en) 1990-09-20
NZ232809A (en) 1992-05-26
DK0387867T3 (da) 1993-06-01
PT93424A (pt) 1990-11-07
CA2010635C (en) 2001-03-06
FI901289A0 (fi) 1990-03-15
NO901198L (no) 1990-09-17
EP0387867A1 (de) 1990-09-19

Similar Documents

Publication Publication Date Title
US5061721A (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
AU622630B2 (en) D-cycloserine and its prodrugs as cognitive enhancers
US20230134844A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US20060211686A1 (en) Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
JP2023534189A (ja) Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法
US5187171A (en) Use of a glycine b partial agonist as an antipsychotic
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US6656962B2 (en) Use of amino-isoxazolidone compounds for improvement of lexical priming
US6962921B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
JP2003221337A (ja) 酢酸アミド誘導体を有効成分とする痴呆症治療剤
WO1996015787A1 (en) Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury

Legal Events

Date Code Title Description
FF Patent granted